Search research articles
Contact Us
Filters
Showing results (61-70 of 99) with videos related to
Page
of 10
Sort By:
Journal Der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG
|
March 10, 2019
Primary cutaneous diffuse large B-cell lymphoma, NOS and leg type: Clinical, morphologic and prognostic differences
Moritz Felcht, Claus-Detlev Klemke, Jan Peter Nicolay, et al.
Journal Der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG
|
March 29, 2019
Primär kutanes diffus-großzelliges B-Zell-Lymphom, NOS oder leg type: klinische, morphologische und prognostische Unterschiede
Moritz Felcht, Claus-Detlev Klemke, Jan Peter Nicolay, et al.
Cancer Immunology, Immunotherapy : CII
|
October 28, 2021
Clinical determinants of long-term survival in metastatic uveal melanoma
Elias A T Koch, Anne Petzold, Anja Wessely, et al.
Lancet (London, England)
|
May 18, 2020
Adjuvant nivolumab plus ipilimumab or nivolumab monotherapy versus placebo in patients with resected stage IV melanoma with no evidence of disease (IMMUNED): a randomised, double-blind, placebo-controlled, phase 2 trial
Lisa Zimmer, Elisabeth Livingstone, Jessica C Hassel, et al.
Lancet (London, England)
|
September 13, 2022
Adjuvant nivolumab plus ipilimumab or nivolumab alone versus placebo in patients with resected stage IV melanoma with no evidence of disease (IMMUNED): final results of a randomised, double-blind, phase 2 trial
Elisabeth Livingstone, Lisa Zimmer, Jessica C Hassel, et al.
International Journal of Cancer
|
July 8, 2024
Influence of adjuvant therapies on organ-specific recurrence of cutaneous melanoma: A multicenter study on 1383 patients of the prospective DeCOG registry ADOReg
Sebastian A Wohlfeil, Leonie Kranzmann, Christel Weiß, et al.
Journal of the European Academy of Dermatology and Venereology : JEADV
|
March 22, 2025
Early termination does not negatively impact the outcome of adjuvant immunotherapy in melanoma
Dirk Tomsitz, Elisabeth Livingstone, Carmen Loquai, et al.
Journal Der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG
|
January 10, 2018
S2k-Leitlinie - Kutane Lymphome Update 2016 - Teil 2: Therapie und Nachsorge (ICD10 C82 - C86)
Edgar Dippel, Chalid Assaf, Jürgen C Becker, et al.
Frontiers in Oncology
|
October 8, 2021
Digital Quantification of Tumor PD-L1 Predicts Outcome of PD-1-Based Immune Checkpoint Therapy in Metastatic Melanoma
Jan-Malte Placke, Camille Soun, Jenny Bottek, et al.
Journal Der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG
|
December 12, 2017
S2k-Leitlinie - Kutane Lymphome Update 2016 - Teil 1: Klassifikation und Diagnostik (ICD10 C82 - C86)
Edgar Dippel, Chalid Assaf, Jürgen C Becker, et al.
Page
of 10
Search research articles
Search
Showing results (61-70 of 99) with videos related to
Sort By:
Page
of 10
Journal Der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG
|
March 10, 2019
Primary cutaneous diffuse large B-cell lymphoma, NOS and leg type: Clinical, morphologic and prognostic differences
Moritz Felcht, Claus-Detlev Klemke, Jan Peter Nicolay, et al.
Journal Der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG
|
March 29, 2019
Primär kutanes diffus-großzelliges B-Zell-Lymphom, NOS oder leg type: klinische, morphologische und prognostische Unterschiede
Moritz Felcht, Claus-Detlev Klemke, Jan Peter Nicolay, et al.
Cancer Immunology, Immunotherapy : CII
|
October 28, 2021
Clinical determinants of long-term survival in metastatic uveal melanoma
Elias A T Koch, Anne Petzold, Anja Wessely, et al.
Lancet (London, England)
|
May 18, 2020
Adjuvant nivolumab plus ipilimumab or nivolumab monotherapy versus placebo in patients with resected stage IV melanoma with no evidence of disease (IMMUNED): a randomised, double-blind, placebo-controlled, phase 2 trial
Lisa Zimmer, Elisabeth Livingstone, Jessica C Hassel, et al.
Lancet (London, England)
|
September 13, 2022
Adjuvant nivolumab plus ipilimumab or nivolumab alone versus placebo in patients with resected stage IV melanoma with no evidence of disease (IMMUNED): final results of a randomised, double-blind, phase 2 trial
Elisabeth Livingstone, Lisa Zimmer, Jessica C Hassel, et al.
International Journal of Cancer
|
July 8, 2024
Influence of adjuvant therapies on organ-specific recurrence of cutaneous melanoma: A multicenter study on 1383 patients of the prospective DeCOG registry ADOReg
Sebastian A Wohlfeil, Leonie Kranzmann, Christel Weiß, et al.
Journal of the European Academy of Dermatology and Venereology : JEADV
|
March 22, 2025
Early termination does not negatively impact the outcome of adjuvant immunotherapy in melanoma
Dirk Tomsitz, Elisabeth Livingstone, Carmen Loquai, et al.
Journal Der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG
|
January 10, 2018
S2k-Leitlinie - Kutane Lymphome Update 2016 - Teil 2: Therapie und Nachsorge (ICD10 C82 - C86)
Edgar Dippel, Chalid Assaf, Jürgen C Becker, et al.
Frontiers in Oncology
|
October 8, 2021
Digital Quantification of Tumor PD-L1 Predicts Outcome of PD-1-Based Immune Checkpoint Therapy in Metastatic Melanoma
Jan-Malte Placke, Camille Soun, Jenny Bottek, et al.
Journal Der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG
|
December 12, 2017
S2k-Leitlinie - Kutane Lymphome Update 2016 - Teil 1: Klassifikation und Diagnostik (ICD10 C82 - C86)
Edgar Dippel, Chalid Assaf, Jürgen C Becker, et al.
Page
of 10